Anoro Ellipta

Indicated For

Chronic Obstructive Pulmonary Disease (COPD)

About This Medication

# GSK Patient Assistance Program Patient Guide: How to Get Anoro Ellipta at Low or No Cost Anoro Ellipta (umeclidinium vilanterol) is a once-daily inhaled powder prescription medicine used for long-term maintenance treatment of **chronic obstructive pulmonary disease (COPD)**, including chronic bronchitis and emphysema, to improve breathing and reduce flare-ups. The **GSK Patient Assistance Program**, offered through the independent GSK Patient Access Programs Foundation, provides this medication at no cost to eligible uninsured or Medicare patients who meet income guidelines and other criteria. ## About Anoro Ellipta **Anoro Ellipta** combines two active ingredients: umeclidinium, an anticholinergic that relaxes muscles around the airways to prevent tightening, and vilanterol, a long-acting beta2-adrenergic agonist (LABA) that also relaxes airway muscles for better airflow.[7][10] It is taken once daily via a handheld Ellipta inhaler and is designed for ongoing COPD management, not for sudden breathing attacks—always keep a rescue inhaler like albuterol on hand for acute symptoms.[3][10] **Important safety notes**: - Not for asthma or acute bronchospasm relief.[3][10] - Contraindicated in patients with severe milk protein allergy or hypersensitivity to umeclidinium, vilanterol, or excipients.[3] - Use caution if you have narrow-angle glaucoma, urinary retention, convulsive disorders, thyrotoxicosis, diabetes, or ketoacidosis.[3] - Possible side effects include nervous system effects (tremor, nervousness), eye problems (glaucoma symptoms like blurred vision or halos), and others—discuss with your doctor and get regular eye exams.[10] Always follow your healthcare provider's instructions and read the full Prescribing Information. ## Who Qualifies for the Program? To qualify for free Anoro Ellipta through the GSK Patient Assistance Program, you must:[2][8] - Live in the United States, Puerto Rico, or U.S. Virgin Islands (for certain products). - Be treated by a U.S.-licensed healthcare provider. - Be **uninsured** or have **Medicare** and meet other requirements. - Meet **financial income eligibility** based on household size and federal poverty level (FPL) guidelines. The program is managed by a 501(c)(3) charitable foundation separate from GlaxoSmithKline (GSK) and does not constitute health insurance.[1] ## Income Eligibility Breakdown Eligibility is based on household income, typically at or below specific thresholds tied to the FPL (exact percentage not specified, but examples provided for a household of 2-4).[8] Specific thresholds were not fully detailed in all sources, but here's a breakdown from program materials: | Household Size | Maximum Annual Income | |---------------|-----------------------| | 2 | $36,000 | | 3 | $43,200 | | 4 | $50,400 | | Each additional person | Add $7,200 | *Notes*: Thresholds are subject to change and based on current FPL. Contact the program at (866) 728-4368 to confirm your household's eligibility, as exact FPL percentage (e.g., 400% or similar) isn't specified here. Provide proof of total household income.[8] ## Insurance Requirements You must be **uninsured** or enrolled in **Medicare** (Parts A/B/D) without other coverage that pays for Anoro Ellipta. Patients with private insurance, Medicaid, or other programs may not qualify—check with the program for details.[2] The program helps bridge gaps for those struggling with costs despite Medicare.[1][2] ## Step-by-Step Application Process The program offers **multiple application methods** for flexibility:[1][9] 1. **Call the hotline**: Dial (866) 728-4368 (Monday-Friday, typical business hours) to speak with a representative who can guide you, send forms, or assist over the phone.[9] 2. **Download and mail**: Visit gskforyou.com or gskpaf.org to find the application (or request via phone). Complete it with your doctor. 3. **Fax or mail**: Send to PO Box 220590, Charlotte, NC 28222-0590 or fax as instructed.[9] **Required Documents** (gather these before starting): - **Proof of income** (e.g., tax returns, pay stubs, W-2s for all household members). - **Proof of residency** (e.g., utility bill, lease). - **Prescription** from a U.S.-licensed healthcare provider specifying Anoro Ellipta. - Medicare card (if applicable) or proof of no insurance.[2][6] Your doctor may need to complete a portion. Applications are reviewed holistically. ## Timeline and Delivery Expect **2-4 weeks** for processing after submission—plan ahead to avoid gaps in treatment.[Program details] If approved, medication is **shipped directly to your home** at no cost, typically for a 12-month supply (subject to reauthorization).[1][2] Track status by calling (866) 728-4368. ## Reauthorization and Refills **Reauthorization is required** annually or as specified. Submit updated income proof and prescription before your supply ends to continue receiving medication seamlessly.[Program details][2] ## Alternatives if Denied or Ineligible - **GSKForYou copay programs**: Eligible commercially insured patients may pay as low as $35 per prescription (terms apply).[10] - **Simplefill**: Free service matches you to assistance programs; apply online or call 1-877-386-0206—they handle paperwork.[7] - **NeedyMeds or RxAssist**: Search for other COPD inhaler aid.[9] - **Doctor samples or GSK Reimbursement Resource Center** for coverage help.[5] - State programs, community health centers, or generic COPD options (discuss with your provider—no biosimilars listed for Anoro).[Program details] If denied, ask for reasons (e.g., income, insurance) and reapply with corrections or explore appeals. ## Disclaimer This guide is for informational purposes only and based on publicly available program details as of the latest sources. Eligibility, terms, and income thresholds can change—**always verify directly with GSK Patient Assistance at (866) 728-4368 or gskforyou.com**. Not medical or legal advice. Consult your healthcare provider for treatment decisions. Programs do not guarantee approval and are subject to availability.[1][2][8] (Word count: 1028)

Program information last verified: March 25, 2026